fbpx

News

Lundbeckfonden Ventures News

Paris, France and Cambridge, MA, USA – August 3, 2020   ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, notes a new academic publication describing the creation of the most comprehensive and unified catalog to-date of genomic and proteomic data from the human gut microbiome....
Cambridge, UK and Indianapolis, US – 9 March 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces...
CAMBRIDGE, Mass., March 05, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the closing of its previously announced rights offering (the “Rights Offering”).  At the closing, Spero sold and...
Cambridge, UK and Indianapolis, US – 2 March 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces...
Cambridge, UK and Indianapolis, US – 2 March 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces...
CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on February 28, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards...
Cambridge, UK and Indianapolis, US – 27 February 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy, will announce its...
BARHEMSYS is the first and only antiemetic to be approved for the rescue treatment of PONV in patients who have failed prior prophylaxis using current standard of care1,2 An estimated 16 million surgical patients each year in the US suffer from PONV despite receiving prophylaxis3 BARHEMSYS is also approved for the prevention of PONV, either...
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will provide a corporate update at the...
1 3 4 5 6 7 68

Lundbeckfonden Ventures

News

Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
23. September 2020
Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma
11. September 2020
Enterome – First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative ‘OncoMimic’ based Immunotherapy Candidate Targeting Adrenal Tumors
9. September 2020